Meeting
2019 ASCO Annual Meeting
Mechanism of biologic therapy for pre B-cell acute lymphoblastic leukemia with CRLF2 overexpression.
Authors
WayAnne Watson
Loma Linda University, Loma Linda, CA
WayAnne Watson , Cornelia Stoian , Jacqueline S. Coats , Hossam AlKashgari , Veriah Vidales , Ineavely Baez , Juliette Personius , Hannah Choi , Benjamin Becerra , Rishikesh Chavan , Muhammad Omair Kamal , Shadi Farzin Gohar , Kimberly J Payne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7035)
DOI
10.1200/JCO.2019.37.15_suppl.7035
Abstract #
7035
Poster Bd #
410
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Bcl-2 family pro-death and pro-survival proteins in Ph-like B cell precursor acute lymphoblastic leukemia.
First Author: Muhammad Omair Kamal
First Author: Jayastu Senapati
Poster
2019 ASCO Annual Meeting
Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.
First Author: Paul B. Koller
Poster
2014 ASCO Annual Meeting
A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).
First Author: Sarah K. Tasian